Patent US3968243A successfully refreshed from Google Patents.
US3968243A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted guanidine compounds in the treating of arrythmias
Assignee: SmithKline Beecham Corp
•
Filing: 1974-01-21
•
Granted: 1976-07-06
•
Expires: 1994-01-21
Abstract
Abstract N- substituted - guanidines having antifibrillatory activity; non-toxic salts thereof; pharmaceutical compositions thereof; and their use in treating cardiac fibrillations.
Inventors
- 👤 Robert Arthur Maxwell
- 👤 Eric Walton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 08:48
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/155
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
98 words
A method for the treatment of cardiac arrhythmias in a mammal which has had cardiac arrythmias which comprises the administration to the mammal of a non-toxic, effective antiarrhythmic treatment amount of a pharmaceutically acceptable acid addition salt of the compound of the formula ##EQU11## wherein `Aralkyl` is selected from the group consisting of unsubstituted benzyl and β-phenethyl, two of the groups R 1 , R 2 and R 3 are methyl and the third group is hydrogen, provided always that R 2 and R 3 are both methyl and R 1 is hydrogen when `Aralkyl` is unsubstituted benzyl.
Claim 2
Independent Claim
98 words
A method for the treatment of cardiac arrhythmias in a mammal which has had cardiac arrythmias which comprises the administration to the mammal of a non-toxic, effective antiarrhythmic treatment amount of a pharmaceutically acceptable acid addition salt of the compound of the formula ##EQU11## wherein `Aralkyl` is selected from the group consisting of unsubstituted benzyl and β-phenethyl, two of the groups R 1 , R 2 and R 3 are methyl and the third group is hydrogen, provided always that R 2 and R 3 are both methyl and R 1 is hydrogen when `Aralkyl` is unsubstituted benzyl.
Claim 3
Dependent Claim
25 words
A method according to claim 1 wherein the amount is 1 to 10 mg. of the compound per kg. mammal bodyweight calculated as the base.
Claim 4
Dependent Claim
19 words
A method as claimed in claim 1 in which the amount is 100 to 600 mg. calculated as base.
Claim 5
Dependent Claim
31 words
A method according to claim 1 in which the compound is in the form of an acid addition salt selected from the group consisting of the chloride, sulphate and p-toluenesulphonate salts.
Claim 6
Independent Claim
36 words
A method of treatment of cardiac arrhythmias in a mammal which has had cardiac arrythmias which comprises administering to the mammal an effective cardiac arrhythmia treatment amount of a pharmaceutically acceptable acid addition salt of N-benzyl-N',N'-dimethylguanidine.
Claim 7
Independent Claim
36 words
A method of treatment of cardiac arrhythmias in a mammal which has had cardiac arrythmias which comprises administering to the mammal an effective cardiac arrhythmia treatment amount of a pharmaceutically acceptable acid addition salt of N-benzyl-N',N'-dimethylguanidine.
Claim 8
Dependent Claim
22 words
A method according to claim 5 wherein the effective amount is 1 to 10 mg. of the base /kg. of mammal bodyweight.
Claim 9
Dependent Claim
12 words
A method according to claim 6 wherein the mammal is a human.
Claim 10
Dependent Claim
12 words
A method according to claim 5 wherein the mammal is a human.
Claim 11
Dependent Claim
12 words
A method according to claim 5 wherein the arrhythmia is ventricular fibrillation.
Claim 12
Dependent Claim
18 words
A method according to claim 6 wherein the arrhythmias which are treated are ventricular fibrillations or atrial fibrillations.
Claim 13
Dependent Claim
12 words
A method according to claim 10 wherein the mammal is a human.
Claim 14
Dependent Claim
17 words
A method according to claim 5 wherein the arrhythmias which are treated are ventricular or atrial fibrillations.
Claim 15
Dependent Claim
12 words
A method according to claim 12 wherein the mammal is a human.
Claim 16
Dependent Claim
23 words
A method according to claim 9 in which an effective amount is 1 to 10 mg. of the base /kg. of mammal bodyweight.
Claim 17
Dependent Claim
13 words
A method according to claim 14 in which the mammal is a human.
Claim 18
Dependent Claim
13 words
A method according to claim 1 in which the compound is N-β-phenethyl-N' ,N"-dimethylguanidine.
Claim 19
Dependent Claim
25 words
A method according to claim 16 in which the amount is 1 to 10 mg. of the compound per /kg. mammal bodyweight calculated as base.
Claim 20
Dependent Claim
18 words
A method according to claim 16 in which the amount is 100 to 600 mg. calculated as base.
Claim 21
Dependent Claim
14 words
The method of claim 16 in which the arrythmias are ventricular or atrial fibrillations.
Claim 22
Dependent Claim
12 words
The method of claim 19 in which the arrythmias are ventricular fibrillations.
Claim 23
Dependent Claim
17 words
The method of claim 20 in which the amount is 100 to 600 mg. calculated as base.
Claim 24
Dependent Claim
40 words
A pharmaceutical composition in solid dosage unit form adapted for administration to treat or suppress arrhythmias, comprising per dosage unit an effective arrhythmia treatment or suppression amount of a pharmaceutically acceptable salt of N-benzyl-N',N'-dimethylguanidine and a therapeutically acceptable carrier therefor.
Claim 25
Dependent Claim
40 words
A pharmaceutical composition in solid dosage unit form adapted for administration to treat or suppress arrhythmias, comprising per dosage unit an effective arrhythmia treatment or suppression amount of a pharmaceutically acceptable salt of N-benzyl-N',N'-dimethylguanidine and a therapeutically acceptable carrier therefor.
Claim 26
Dependent Claim
14 words
A pharmaceutical composition according to claim 22 in a form adapted for oral administration.
Claim 27
Dependent Claim
13 words
A pharmaceutical composition according to claim 23 in the form of a tablet.
Claim 28
Dependent Claim
23 words
A pharmaceutical composition according to claim 22 in the form of a discrete dosage unit containing 100 to 600 mg. of the base.
Claim 29
Dependent Claim
25 words
A pharmaceutical composition according to claim 22 wherein the acid addition salt is selected from the group consisting of the chloride, sulphate and p-toluenesulphonate salts.
References Cited (Backward Citations)
US3168562A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-07-06 | 1980-01-05 | 1980-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-07-06 | 1984-01-05 | 1984-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-07-06 | 1988-01-05 | 1988-07-06 | $7700.00 | Window Closed / Lapsed |